Darwin AG will participate in two capital markets conferences in spring 2026, presenting its equity story and recent developments to investors. The company will attend both the Invest conference in Stuttgart and the Equity Forum German Spring Conference in Frankfurt, with management available for one-on-one meetings at each event.
The Invest conference, described as the leading expo for finance and investment, will take place from April 17 to 18, 2026, at Messe Stuttgart. Targeted primarily at retail investors, the conference covers a broad range of investment types and topics across the finance sector. Under the theme "Invest in the Future of Precision Health," Dr. Daniel Wallerstorfer, CEO of Darwin AG, will present the company's equity story on April 17 at 5:30 p.m., providing insight into how personalized solutions are shaping tomorrow's healthcare market. Interested visitors can meet Darwin AG management at Hall 4, Booth 4E32 to learn about personalized health and the company's products. Further information about Invest can be found at https://darwin-biotech.com/.
The Equity Forum's 2026 Spring Conference represents a different audience, being a MiFID II-compliant professional event for institutional investors, financial analysts, venture capital, and private equity investors. Scheduled for May 11 to 12, 2026, at the Flemings Selection Hotel in Frankfurt, this conference will feature Darwin AG presenting a corporate update and audited financial results for 2025. The presentation on May 12 from 9:20 a.m. to 9:55 a.m. will include an operational and strategic outlook alongside the financial results, with the 2025 consolidated financial statements published in the Annual Report on the same day. Following the presentation, Dr. Wallerstorfer will be available for individual meetings scheduled through the conference website. More information about the 2026 German Spring Conference can be found at https://darwin-biotech.com/.
These dual conference appearances highlight Darwin AG's strategic positioning within the growing precision health sector. The company, headquartered in Munich, operates as a European healthcare company focused on human genetics and developing personalized products based on genetic analysis. Its laboratory conducts genetic analyses used in disease diagnosis, treatment, and prevention, as well as in creating individually tailored nutritional supplements and cosmetics. Darwin AG also partners with healthcare professionals to optimize patient care through genetic predisposition analysis and holds investments in innovative biotech, healthcare, and life sciences companies.
For business and technology leaders, Darwin AG's conference participation signals the maturation of personalized healthcare as an investment category. The company's approach represents the intersection of biotechnology, data analytics, and consumer health products, creating new market opportunities while addressing individual health needs. As genetic testing becomes more accessible and affordable, companies like Darwin AG are positioned to transform traditional healthcare models through precision-based solutions. The dual-audience approach—presenting to both retail investors at Invest and institutional investors at the Equity Forum—demonstrates the company's comprehensive capital markets strategy and the broadening appeal of healthcare technology investments across different investor types.
